Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Amgen (AMGN) Friedman Billings Ramsey Jim Reddoch Downgrade Market perform (from market outperform)
Reddoch thinks that Medicare reimbursement changes next year will prompt cancer patients to receive certain treatments in the hospital rather than at a clinic. As a result, he lowered his 2005 sales estimates for cancer anemia drug

Read the full 598 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE